Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00001271 · ClinicalTrials.gov registry record · Phase 1
A Phase I Study of Continuous Infusion Immunotoxin IgG-RFB4-SMPT-dgA in Refractory CD22 Positive B-Cell Lymphoma
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT00001271: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00001271 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 24 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00001271, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
Patients with CD22(+) B-cell lymphomas will be treated with escalating doses as a 192 hr infusion of immunotoxin in a Phase I study to determine dose limiting toxicity evidence of response.
Interventions
- DRUG IgG-RFB4-SMPT-dgA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 1991-07 |
| Est. Completion | 2001-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00001271
The ClinicalTrials.gov registry entry for NCT00001271 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which IgG-RFB4-SMPT-dgA is the first listed.
NCT00001271 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00001271 about?
NCT00001271 is a clinical study titled "A Phase I Study of Continuous Infusion Immunotoxin IgG-RFB4-SMPT-dgA in Refractory CD22 Positive B-Cell Lymphoma". Patients with CD22(+) B-cell lymphomas will be treated with escalating doses as a 192 hr infusion of immunotoxin in a Phase I study to determine dose limiting toxicity evidence of response.
What is the current status of trial NCT00001271?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 1991-07. Estimated completion is 2001-04.
What interventions are being tested in trial NCT00001271?
The interventions under investigation include: IgG-RFB4-SMPT-dgA (DRUG).
Who is sponsoring clinical trial NCT00001271?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.